Genfit Positions To Battle Intercept On Both NASH And PBC Fronts
This article was originally published in The Pink Sheet Daily
Executive Summary
While beginning to enroll the Phase III trial of elafibranor in NASH, Genfit also plans to study the drug in PBC, an indication in which top competitor Intercept could receive FDA approval this quarter.
You may also be interested in...
Genfit Says Safety/Tolerability Will Give Elafibranor An Edge In NASH
Lack of pruritus and a positive cardiometabolic profile could give elafibranor an advantage as it competes with Intercept’s Ocaliva to be the first drug therapy to market in NASH. The French biotech also is working on a biomarker algorithm to optimize patient selection.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.